● Green Hygienics has launched TruLife Biotech LLC. to focus on the development and advancement of innovative cannabinoid-based nutraceutical and skincare products and brands
● The global industrial hemp market was valued at $5.66 billion in 2020 and is expected to reach a value of $27.72 billion by 2028, growing at a CAGR of 25.17%
● Hemp-derived cannabinoids have been studied for the last 20 years with nothing more than pre-clinical data but the new collaboration with Cinvestav and the creation of TruLife Biotech can help answer these questions and develop the products necessary for ECS deficiencies
Green Hygienics Holdings (OTCQB: GRYN), a California-based tech-driven enterprise focused on the high standard cultivation of industrial hemp and manufacturing of pharmaceutical-grade bioactive cannabinoids, recently announced that to advance R&D efforts, it has entered into a scientific research collaboration agreement with Cinvestav, the Center for Research and Advanced Studies of the National Polytechnic Institute of Mexico (Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional) (https://ibn.fm/8UnHo).
Cinvestav is a high-ranked, leading Mexican multidisciplinary scientific research institute that will work with Green Hygienics in R&D efforts to develop cannabinoid-based products targeting the endocannabinoid system (“ECS”) deficiencies in animals and humans. Cinvestav ranks fourth among Latin American research centers and 118th worldwide.
Green Hygienics is also launching TruLife Biotech, LLC. to advance studies in hemp-derived cannabinoid therapies, like the research conducted with Cinvestav. The focus of TruLife Biotech will be the development and advancement of innovative cannabinoid-based nutraceuticals, skincare products, and wellness brands addressing the ECS deficiencies in humans (https://ibn.fm/rCXOQ).
“This research collaboration will be our first project under TruLife Biotech LLC, a Green Hygienics Company focused on the development and advancement of innovative cannabinoid-based nutraceutical and skincare products and brands,” Chief Scientific Officer Dr. Levan Darjania said. “The collaboration with Cinvestav will augment ongoing efforts by both parties to identify and explore selected cannabinoids and terpenes in planned combinations that may act synergistically to protect against pain development and determine their potential efficacy as pain relievers against inflammatory and neuropathic pain.”
It is the collaborative model that Green Hygienics and Cinvestav will develop that will be used to create proprietary and effective products. “Discovery and development of cannabinoid-based products that are truly effective in producing the desired result are global tasks that are based on multidisciplinary approaches, collaborations, and partnerships. After meeting with leading researchers at Cinvestav’s Mexico City Campus, we are confident in our collaboration on the development of new and efficacious products,” COO Kyle MacKinnon added.
Even though the interaction of hemp-derived cannabinoids and the body’s ECS has been studied for the last 20 years, there is only pre-clinical data available. Still, the question that arises is how much of that data is genuine and useful. The company intends to use the new collaboration and TruLife Biotech formation to help answer these questions and develop the products necessary for ECS deficiencies, according to Dr. Darjania.
To further support the initiative, Green Hygienics has published a White Paper through Nutritional Outlook, an MJH Life Sciences(TM) brand that provides intelligent, well-informed insights and industry updates critical to the manufacturers of dietary supplements, health foods, and nutritional beverages.
The White Paper examines the therapeutic potential for cannabinoid health- and wellness-based products, but underlines the need to develop defined, consistent, and targeted products with established standards. The ultimate goal is to develop and promote scientific evidence-based ECS-modulating cannabinoid products that will be trusted by medical communities, physicians, holistic health practitioners, and wellness-oriented end users (https://ibn.fm/9929I).
According to Dr. Darjania, Green Hygienics remains committed to changing the landscape of the industry and continuing the advancement of its hemp-derived cannabinoid phyto-remedy platform, with TruLife serving as a hub of biotechnology innovations and ultimately securing a strategic advantage in the market by introducing novel cannabinoids and biodelivery methods. These steps will help cement Green Hygienics’ role in the global hemp market, which was valued at $5.66 billion worldwide in 2020. The market is expected to grow at a CAGR of 25.17% from 2021 to 2028, resulting in an estimated value of $27.72 billion by 2028 (https://ibn.fm/mZEGs) and multiple expansion opportunities for Green Hygienics and its portfolio.
About Green Hygienics Holdings Inc.
Green Hygienic Holdings Inc. (OTCQB: GRYN) (“Green Hygienics” or the “Company”) is a California-based innovative, technology-driven enterprise focused on the high standard cultivation and processing of industrial hemp and manufacturing of pharmaceutical-grade bioactive cannabinoids. The Company’s corporate mission is to adhere to the highest standards of operations in consistently delivering safe and premium-quality products to consumers as well as to partner with CPG (consumer packaged goods) and pharmaceutical companies.
Hygienics is the science of preserving and promoting the health of individuals, communities and the planet.
For more information, visit the company’s website at www.GreenHygienics.com.
Follow us on: Facebook, Twitter, and Linkedin
CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS
This document contains forward-looking statements. In evaluating these forward-looking statements, you should consider various factors, including our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement.